We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info.


Supervisory Board

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit. It approves the measures of the Corporate Executive Board in case these are subject to approval by corporate bylaws.

Dr. Wilhelm Moll LL.M.

Chairman of the Supervisory Board

Dr. Moll was born on 31 October 1949 in Gevelsberg, Germany. After his Abitur and subsequent service in the German Federal Border Guard, he studied law in Marburg and Cologne, Germany and in Berkeley, CA, USA. He obtained his doctorate from the Faculty of Law at Cologne University and subsequently a Master of Law at Berkeley, School of Law, University of California.

Dr. Moll worked at the Institute for Labor and Business Law (Institut für Arbeits- und Wirtschaftsrecht) at Cologne University beginning in 1975, initially as a research associate and later as assistant professor. He became a certified attorney of law in 1982 and a partner of the law firm Heuking Kühn Lüer Wojtek. Dr. Moll’s main areas of expertise are employment/labour, corporate and commercial law. His clients include large- (DAX) and mid-sized enterprises. He provides comprehensive legal advice to medium-sized and owner-managed companies around a multitude of problems and issues.

Apart from his legal consultancy and court-related activities, Dr. Moll also has a distinguished reputation for his seminars and lectures, for instance concerning questions about the role of managing director in a GmbH (limited liability company). He is the author of numerous legal publications, the last concerning commentaries on provisions of the German Reorganization Act (Umwandlungsgesetz).

Edouard Croufer

Member of the Supervisory Board

Edouard Croufer was born on 3 May 1947 in Spa, Belgium. He has an M.S. in engineering physics from the University of Liège, Belgium and an M.M.S. from the University of Waterloo, Canada and attended an Advanced Management Program at Harvard Business School. Edouard Croufer has over 30 years of experience in the chemical and pharmaceutical industry and has held many senior positions.

In 1971, Mr Croufer was appointed research engineer at Centre Recherche Metallurgique in Liège, Belgium and from 1973 until 1976 he was professor of data processing at Universidade de Joinville Santa Catarina in Brazil. Between 1976 and 1993, he held various international positions at Exxon Chemical and was President of Exxon Chemical Belgium and Netherlands amongst others. A member of UCB’s Executive Committee from 1993 until 2004, Mr Croufer was Director General for the chemical sector and later Director General for pharma. He went on to become Global Director heading up the global expansion of the Chemical and Health Care practice of Arthur D. Little until 2011.

Mr Croufer is an experienced member of supervisory boards for various corporations in the chemical and pharmaceutical sector and previously served as a member of our advisory board between 2004 and 2008. In terms of areas of expertise, Mr Croufer has been engaged extensively in Biopharmaceuticals and is particularly experienced in business strategy, organization design, technology and innovation management and operational excellence.

Dr. Thomas Ludwig

Member of the Supervisory Board

Dr. Ludwig was born in Vechta, Germany on 21 November 1948. After studying mathematics and business administration in Göttingen, Freiburg, Glasgow and Bonn, he received a degree in mathematics and became a doctor of political science at Bonn University.

Dr. Ludwig has over 30 years of experience in business management positions. Following a trainee program with the German Steel Federation, he launched his career at Klöckner Werke AG, then moved to the trading house Klöckner & Co AG as a member of the Executive Board in charge of raw materials, recycling and environmental technology. Dr. Ludwig then took a position within the Thyssen Corporation (now known as ThyssenKrupp) building up their service segment and later becoming an Executive Board member. From 2003 to 2009, he was chairman of the Executive Board of Klöckner & Co SE, successfully taking them to the stock exchange and following acquisition by Lindsay Goldberg, achieving market leadership in Europe and North America.

Since January 2010, Dr. Ludwig has been Managing Director and Managing Partner of Lindsay Goldberg Vogel GmbH in Düsseldorf, Germany representing the private equity firm Lindsay Goldberg LLC, New York in Central Europe.

Prof. Dr. Eric-Paul Pâques

Member of the Supervisory Board

Prof. Dr. Eric-Paul Pâques was born in 1954 in Namur, Belgium. He studied chemistry at the Université Catholique de Louvain, Belgium and graduated with a doctorate under the mentoring of Prof. Dr. R. Huber at the Max Planck Institute for Biochemistry, Munich, Germany and Prof. R. R. Crichton in Louvain.

Between 1980 and 1993, Prof. Dr. Pâques worked as head of research for the Behringwerke AG in Marburg, Germany and following his habilitation in 1990,accepted a teaching position as an invited professor at the Catholic University of Louvain.

In 1994 Prof. Dr. Pâques joined the Grünenthal Group as head of Research & Development. As a member of the Corporate Executive Board since 1998 he was responsible for the areas Research & Development, regulatory, safety, intellectual property, business development, M&A and licensing. He was CEO of the Grünenthal Group from June 2013 until his retirement from operational business at the end of 2016.

Prof. Dr. Pâques lectures at the RWTH Aachen University, Germany and is a member of several advisory boards in Europe and the USA.

Dr. Martin Zügel

Member of the Supervisory Board

Dr. Martin Zügel was born on 6 April 1962. After studying medicine in Bochum and Tübingen, Germany and molecular biology with an MSc in Amherst, USA, he received his doctorate in 1989.

Dr. Zügel has more than 20 years of experience in the pharmaceutical industry having held several executive positions. After working in the hematology and oncology departments of the University Hospital Hamburg-Eppendorf, he moved to Boehringer Mannheim GmbH (later Hoffmann La Roche AG) in 1991 and joined B. Braun Melsungen AG as a Member of the Board in 2000. In 2005, he joined Merz Pharmaceuticals as CEO and in 2008, he additionally assumed the role of spokesperson for Merz GmbH & Co. KGaA. Since leaving Merz in 2012, Dr. Zügel has acted as chairman of the supervisory board at Glycotope and Amsilk GmbH and consultant for various companies in the pharmaceutical and biotech industry as well as senior health care advisor for the private equity firm CVC Capital Partners.

Dr. Zügel has also been Chief Executive Officer of Klosterfrau Zürich AG since 2015.